The first half of 2025 has brought major developments in gastroenterology, spanning new drug approvals, trial data, and clinical guidance. Two major FDA approvals expanded the use of IL-23-targeted therapies in Crohn’s disease: mirikizumab (Omvoh) and guselkumab (Tremfya), both showing strong clinical efficacy across trials.
Trending
- Congratulations Dr. Kim on new AAAHC leadership position (AGA)
- When RVUs Go Wrong: Red Flags for Physicians (Medscape)
- GI Side Effects of Immune Checkpoint Inhibitors Linked to Colon Adenoma Risk (GI & Hepatology News)
- Would You Track Your Stools Like You Track Your Steps? (Bloomberg)
- Good news, bad news for gastroenterology (Becker’s GI & Endoscopy)
- Addressing Colonoscopy Burden due to Artificial Intelligence Devices for Polyp Detection (Gastro Journal)
- Gastro Center of Maryland Expands to Bethesda and Silver Spring, Broadening Access to GI Care in the DMV (USA Today)
- To Improve CRC Screening in Patients Aged 45-49, Just Send Them a FIT Kit (GI & Endoscopy News)
